What is NDC 67046-1459?

67046-1459 is the product NDC for Lamivudine, Lamivudine 150 mg/1 tablet, film coated, listed with the FDA by Coupler LLC. It has 1 package NDC, shown above in 10- and 11-digit form.

Coupler LLC, NDC labeler code 67046. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Lamivudine?

25 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Lamivudine NDC 67046-1459 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)67046-1459Labeler and product segments. Claims need a package NDC.

Product NDC at billing width67046-1459Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
67046-1459-3	67046145903	30 TABLET, FILM COATED in 1 BLISTER PACK (67046-1459-3)Marketed from Feb 6, 2025

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Lamivudine
Generic name (nonproprietary): lamivudine
Active ingredients: Lamivudine — 150 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Coupler LLCNDC labeler code 67046
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 090457
Marketing start: Feb 6, 2025
Listing expires: Dec 31, 2026
Other FDA classes: Nucleoside Reverse Transcriptase Inhibitors (Mechanism)
Identifiers: Product ID 67046-1459_2d7daacc-a9ed-2f30-e063-6294a90a4a57SPL ID 2d7daacc-a9ed-2f30-e063-6294a90a4a57SPL set ID 2d7db3b2-9b3c-3031-e063-6294a90a342cRxCUI 199147UNII 2T8Q726O95
Pharmacologic class: Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor; Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N467046145903 followed by a unit qualifier and the quantity

Package 67046-1459-03. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Feb 6, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

Lamivudine is a nucleoside analogue indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. Limitations of Use: The dosage of this product is for HIV-1 and not for HBV. Lamivudine is a nucleoside analogue reverse transcriptase inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. Limitations of Use: The dosage of this product is for HIV-1 and not for HBV. (1)

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 67046-1459

What is NDC 67046-1459?: 67046-1459 is the product NDC for Lamivudine, Lamivudine 150 mg/1 tablet, film coated, listed with the FDA by Coupler LLC. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Lamivudine.
What is the active ingredient?: Lamivudine.
Who is the labeler?: Coupler LLC, NDC labeler code 67046. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Lamivudine?: 25 other product NDCs are listed under this name. See all Lamivudine NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Lamivudine NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Lamivudine	Lamivudine 150 mg/1	Tablet, Film coatedOral	American Health Packaging	60687-720	60687-0720-21
Lamivudine	Lamivudine 150 mg/1	Tablet, Film coatedOral	Macleods Pharmaceuticals Limited	33342-001	33342-0001-09
Lamivudine	Lamivudine 300 mg/1	Tablet, Film coatedOral	Macleods Pharmaceuticals Limited	33342-002	33342-0002-07
lamivudine	Lamivudine 100 mg/1	Tablet, Film coatedOral	Camber Pharmaceuticals, Inc.	31722-001	31722-0001-0231722-0001-60
Lamivudine	Lamivudine 150 mg/1	Tablet, Film coatedOral	Strides Pharma Science Limited	64380-710	64380-0710-03
Lamivudine	Lamivudine 300 mg/1	Tablet, Film coatedOral	Strides Pharma Science Limited	64380-711	64380-0711-04
Lamivudine	Lamivudine 150 mg/1	TabletOral	Ingenus Pharmaceuticals, LLC	50742-623	50742-0623-60
Lamivudine	Lamivudine 300 mg/1	TabletOral	Ingenus Pharmaceuticals, LLC	50742-624	50742-0624-60
Lamivudine	Lamivudine 10 mg/mL	SolutionOral	Rising Pharma Holdings, Inc.	57237-274	57237-0274-24
Lamivudine	Lamivudine 150 mg/1	Tablet, Film coatedOral	Aurobindo Pharma Limited	65862-025	65862-0025-1065862-0025-60

All 26 Lamivudine NDCs

Other NDCs under ANDA 090457

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 090457
Product	Strength	Form · route	Labeler	Product NDC
Lamivudine	Lamivudine 150 mg/1	Tablet, Film coatedOral	Strides Pharma Science Limited	64380-710
Lamivudine	Lamivudine 300 mg/1	Tablet, Film coatedOral	Strides Pharma Science Limited	64380-711